At a glance
- Sermorelin is the first 29 amino acids of human GHRH—the shortest fragment that retains strong GHRH-receptor activity. It gives researchers a defined way to study the pituitary side of growth-hormone release.
- A branded sermorelin product was previously approved in the United States for diagnostic and paediatric use, then discontinued for commercial reasons. That history does not make a current research vial an approved drug or establish anti-aging claims.
- Compare GHRH-receptor signalling with direct growth-hormone exposure to separate upstream release from downstream receptor activity.
- Use time-resolved sampling when the question involves pulsatile pituitary release rather than a single end-point concentration.
What SERMORELIN is—and what the name does not establish
Sermorelin is the first 29 amino acids of human GHRH—the shortest fragment that retains strong GHRH-receptor activity. It gives researchers a defined way to study the pituitary side of growth-hormone release.
Sermorelin activates GHRH receptors on pituitary somatotroph cells, which can increase pulsatile growth-hormone release and downstream IGF-1 signalling. It works upstream of growth hormone, unlike somatropin, and through a different receptor from ghrelin agonists such as ipamorelin.
Questions to settle before interpreting a result
A useful SERMORELIN study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Compare GHRH-receptor signalling with direct growth-hormone exposure to separate upstream release from downstream receptor activity.
- Use time-resolved sampling when the question involves pulsatile pituitary release rather than a single end-point concentration.
- Include a ghrelin-receptor agonist comparator when studying how GHRH and GHSR routes differ or converge.
How to read the SERMORELIN evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Human physiology
- Design
- GHRH(1–29) can stimulate pituitary GH release
- Finding
- Sermorelin’s core pharmacology is grounded in human GHRH physiology and historical diagnostic development. That supports its use as a pathway reference, not broad claims about rejuvenation or performance.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Important distinction
- Design
- Upstream stimulation is not direct HGH replacement
- Finding
- Sermorelin relies on a responsive pituitary and endogenous release machinery. Somatropin activates the growth-hormone receptor directly after administration; the two designs answer different research questions.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Approval context
- Design
- Historical approval was narrow and product-specific
- Finding
- The discontinued branded product’s diagnostic and paediatric history does not establish current approval, anti-aging effectiveness, or equivalence for research material.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
A branded sermorelin product was previously approved in the United States for diagnostic and paediatric use, then discontinued for commercial reasons. That history does not make a current research vial an approved drug or establish anti-aging claims.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Once-daily subcutaneous growth hormone-releasing hormone (1-29) in growth-hormone-deficient childrenPubMed-indexed clinical study · 1996
Human study of a defined GHRH(1-29) product and paediatric population. It does not establish anti-aging, performance, or equivalence claims for an independently sourced vial.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for SERMORELIN
This compound is not currently stocked. Add it to your five-choice catalogue ballot.